Geographical Group Reporting Submission
Cochrane Mexico (Universidad Marista de Merida)
Felix-Julian Campos-Garcia
Cochrane Protocol (On going Peer Review): C-type natriuretic peptide analogues for improving linear growth in children with achondroplasia
Cochrane India (All India Institute of Medical Sciences)
No
Felix Julian Campos Garcia
fcampos@marista.edu.mx
fcampos@marista.edu.mx
Written report or publication
This protocol addresses an important evidence gap in the management of achondroplasia, the most common skeletal dysplasia, for which C-type natriuretic peptide analogues such as vosoritide have emerged as disease-modifying therapies. Current clinical studies suggest improvements in growth velocity and related outcomes in affected children.
Duration: January 2026 – June 2026 (protocol development phase).
June 2026 - on going: Peer review
Reach: International. The review topic is relevant to clinicians, geneticists, endocrinologists, pediatricians, policy makers, patients, families, and rare disease organizations worldwide. The completed review is expected to inform clinical practice and future guideline development regarding pharmacological interventions for achondroplasia.
Expected impact: The review will provide a rigorous synthesis of the benefits and harms of CNP analogues in children with achondroplasia, supporting evidence-informed decision making for patients, families, healthcare professionals, and health systems. The project also strengthens systematic review capacity within the Cochrane community and among early-career researchers involved in rare disease research.
Return on investment: The protocol establishes a transparent and reproducible framework for evidence synthesis in a rapidly evolving therapeutic area, maximizing the value of existing clinical trial data and reducing duplication of effort. The resulting review is expected to serve as a key reference for clinicians, researchers, patient organizations, and policy makers evaluating emerging treatments for achondroplasia.
Duration: January 2026 – June 2026 (protocol development phase).
June 2026 - on going: Peer review
Reach: International. The review topic is relevant to clinicians, geneticists, endocrinologists, pediatricians, policy makers, patients, families, and rare disease organizations worldwide. The completed review is expected to inform clinical practice and future guideline development regarding pharmacological interventions for achondroplasia.
Expected impact: The review will provide a rigorous synthesis of the benefits and harms of CNP analogues in children with achondroplasia, supporting evidence-informed decision making for patients, families, healthcare professionals, and health systems. The project also strengthens systematic review capacity within the Cochrane community and among early-career researchers involved in rare disease research.
Return on investment: The protocol establishes a transparent and reproducible framework for evidence synthesis in a rapidly evolving therapeutic area, maximizing the value of existing clinical trial data and reducing duplication of effort. The resulting review is expected to serve as a key reference for clinicians, researchers, patient organizations, and policy makers evaluating emerging treatments for achondroplasia.